Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment

Pharmacological Reports

Volumn 61, Issue 3, 2009, Pages 436-447

  Gałecki, Piotr ^a   Szemraj, Janusz ^a   Bieńkiewicz, Małgorzata ^a   Florkowski, Antoni ^a   Gałecka, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Antioxidant defense; Depressive disorder; Fluoxetine; Lipid peroxidation

Indexed keywords

ANTIOXIDANT; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; FLUOXETINE; MALONALDEHYDE;

ARTICLE; BLOOD CHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ERYTHROCYTE LEVEL; FEMALE; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MAJOR DEPRESSION; MALE; OXIDATIVE STRESS; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; REMISSION; SCORING SYSTEM;

ACUTE DISEASE; ADULT; ANTIOXIDANTS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; HUMANS; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; SEROTONIN UPTAKE INHIBITORS;

EID: 67651148093     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70084-2     Document Type: Article

References (76)

1. 2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radical Biol Med, 2006, 40, 376-387.
2. Altindag O, Karakoc M, Kocyigit A, Celik H, Soran N: Increased DNA damage and oxidative stress in patients with rheumatoid arthritis. Clin Biochem, 2007, 40, 167-171.
3. American Psychiatry Association. In: Diagnostic and statistical Manual of Mental Disorder, 4th Edition, American Psychiatric Press, Washington, DC, 1994.
4. Atmaca M, Tezcan E, Kuloglu M, Ustundag B, Tunckol H: Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment. Eur Arch Psychiatry Clin Neurosci, 2004, 254, 231-235.
5. Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida L, Nardin P, Cunha A et al.: Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatry Res, 2007, 523-529.
6. Andreazza AC, Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, Yatham LN: Oxidative stress markers in bipolar disorder: A meta-analysis. J Affect Disord, 2008, 6, 111, 135-144.
7. Balboa M, Balsinde J: Oxidative stress and arachidonic acid mobilization. Biochem Biophys, 2006, 1761, 385-391.
8. Bartosz G: Other face of oxygen (Polish). PWN, Warsaw, 2004, 389-394.
9. Beers R, Sizer T: Spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem, 1952, 195, 133-140.
10. Belowski D, Kowalski J, Madej A, Herman Z: Influence of antidepressant drugs on macrophage cytotoxic activity in rats. Pol J Pharmacol, 2004, 56, 837-842.
11. Benzie I, Strain J: Ferric reducing/antioxidant power assay: antioxidant activity of biological fluids and modified version for simultaneous measurement of total power and ascorbic acid concentration. Methods Enzymol, 1999, 299, 15-27.
12. Benzie I, Strain J: The ferric reducing ability of plasma (FRAP) as a measure of "Antioxidant power": the FRAP assay. Anal Biochem, 1996, 239, 70-76.
13. Bilici M, Efe H, Koroglu A, Uydu HA, Bekaroglu M, Deger O: Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord, 2001, 64, 43-51.
14. Brookes PS, Yoon Y, Robotam JL, Anders MW: Calcium, ATP, and ROS: a mitochondrial love hate triangle. Am J Physiol Cell Physiol, 2004, 287, 817-833.
15. Brustoilim D, Ribeiro-dos-Santos R, Kast R, Altschuler E, Soares M: A new chapter opens in anti-inflammatory treatments: The antidepressants bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int. Immunopharmacol, 2006, 6, 903-907.
16. Del Rio D, StewarAJ, Pellegrini N: A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis, 2005, 15, 316-328.
17. Droge W: Free radicals in the physiological control of cell function. Physiol Rev., 2002, 82, 47-95.
18. Dubas-Ślemp H, Marmurowska-Michałowska H, Szuster-Ciesielska A, Kamińska T, Kandefer-Szerszeń M: The role of cytokines in depression (Polish). Psychiatria Polska, 2003, 37, 787-798.
19. Dunn AJ, Swiergiel AH, de Beaurepaire R: Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev, 2005;29,891-909.
20. Fialkow L, Wang Y, Downey GP: Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radical Biol Med, 2007, 42, 153-164.
21. Gałecki P, Kedziora J, Florkowski A, Gałecka E: Lipid peroxidation and Copper-Zinc Superoxide Dismutase activity in patients treated with fluoxetine during the first episode of depression (Polish). Psychiatria Polska, 2007, 41, 615-624.
22. Gougerot-Pocidalo MA, el Benna J, Elbim C, Chollet-Martin S, Dang MC: Regulation of human neutrophil oxidative burst by pro-and anti inflammatory cytokines. J Soc Biol, 2002, 196, 37-46.
23. Guzik TJ, Korbut R, Adamek-Guzik T: Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol, 2003, 54, 469-487.
24. Gutteridge JMC: Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem, 1995, 41, 1819-1828.
25. 2 murine microglial cells. Neurosci Lett, 2006, 397, 185-189.
26. Halliwell B: Oxidative stress and neurodegeneration: Where are we now. J Neurochem, 2007, 97,1634-1658.
27. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry, 1960, 23, 56-62.
28. Hendriks J, Teunissen Ch, de Vries H, Dijkstra Ch: Macrophages and neurodegeneration. Brain Res Rev, 2005, 48, 185-195.
29. Herken H, Gurel A, Selek S, Armutcu F, Ozen M, Bulut M, Kap O et al.: Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: Impact of antidepressant treatment. Arch Med Res, 2007, 38, 247-252.
30. Hwang ES, Kim GH: Biomarkers of oxidative stress status of DNA, lipids, and proteins in vitro and in vivo cancer research. Toxicology, 2007, 5, 229, 1-10.
31. Im J, Kim D, Paik S, Han P:Cycloooxygenase-2-dependent neuronal death proceeds via superoxide anion generation. Free Radical Biol Med, 2006, 41, 960-972.
32. Karihtala P, Soini Y: Reactive oxygen species and anti-oxidant mechanisms in human tissues and their relation to malignancies. APMIS, 2007, 115, 81-103.
33. Khanzode SD, Dakhale G.N, Khanzode SS, Saoji A, Palasodkar R: Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep, 2003, 8, 365-370.
34. Kim D, Li H, Yoo K, Lee B, Hwang I, Won M: Effects of fluoxetine on ischemic cells and expressions in BDNF and some antioxidants in the gerbil hippocampus CA1 region induced by transient ischemia. Exp Neurol, 2007, 204, 748-758.
35. Kolla N, Wei Z, Richardson JS, Li X: Amitryptyline and fluoxetine protect PC12 cells from cell death induced by hydrogen peroxide. J Psychiatry Neurosci, 2005, 30, 196-201.
36. Kronfol Z, Remick D: Cytokines and the Brain: implications for clinical psychiatry. Am J Psychiatry, 2000, 157, 683-694.
37. Kubera M, Maes M, Kenis G, Kim Y, Lasoń W: Effects of serotonin and serotoninergic agonists and antagonists on the production of tumor necrosis factor α and interleukin-6. Psychiatry Res, 2005, 134, 251-258.
38. Kunz M, Gama CS, Andreazza AC, Salvador M, Ceresér KM, Gomes FA, Belmonte-de-Abreu PS et al.: Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32, 1677-1681.
39. Lee AL, WO O, Sapolsky RM: Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord, 2002, 4, 117-128.
40. Leonard BE: The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry, 2001, 25, 767-780.
41. Leonard BE: Inflammation, depression and dementia: are they connected? Neurochem Res, 2007, 32, 1749-1756.
42. Lesgards JF, Durand Ph, Lassarre M, Stocker P, Lesgards G, Lanteaume A, Prost M, Lehucher-Michel M: Assessment of lifestyle effects on the overall antioxidant capacity of healthy subjects. Environ Health Perspect, 2002, 110, 479-487.
43. Li Y, Zhang J: Serum concentrations of antioxidant vitamins and carotenoids are low in individuals with a history of attempted suicide. Nutr Neurosci, 2007, 10, 51-58.
44. Little C, O'Brian P: An intracellular GSH-peroxidase with a lipid peroxide substrate. Biochem Biophys Res Commun, 1968, 31, 145-150.
45. Lucas S, Rothwell NJ, Gibson RM: The role of inflammation in CNS injury disease. Br J Pharmacol, 2006, 147, 232-240.
46. Maes M, Christophe A, Delange J, Neels H, Scharpe S, Meltzer HY: Lowered omega 3 polyunsaturated fatty acids in serum phospholipids and cholesterol esters of depressed patients. Psychiatry Res, 1999, 85, 275-291.
47. Maes M, Smith R, Scharpe S: The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology, 1995, 20, 111-116.
48. Maes M, Vos N, Pioli R, Demedts P, Wauters A, Neels H, Christophe A: Lower serum vitamin E concentration in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord, 2000, 58, 241-146.
49. Machado-Vieira R, Soares JC: Treatment - resistant mood disorders. Rev Bras Psiquiatr, 2007, 29, 48-54.
50. Manuel y Keenoy B, Moorkens G, Vertommen J, Noe M, Neve J, De Leeuw I: Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue: effects of supplementation with magnesium. J Am Coll Nutr, 2000, 19, 374-382.
51. McEwen BS, Magarinos AM: Stress and hippocampal plasticity: Implications for the pathophysiology of affective disorders. Hum Psychopharmacol, 2001, 16, 7-19.
52. Misra HP, Fridovich J: The role of superoxide anion in the autooxidation of epinephrine and a simple assay superoxide dismutase. J Biol Chem, 1972, 3170-3173.
53. Niki E, Yoshida Y, Saito Y, Noguchi N: Lipid peroxidation: Mechanisms, inhibition, and biological effects. Biochem Biophys Res Commun, 2005, 338, 668-676.
54. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O: Anti-oxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol, 2004, 19, 89-95.
55. Ozgocmen S, Ozyut H, Sogut S, Akyol O, Aridcoglu O, Yildizhan H: Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int, 2006, 26, 598-603.
56. Placer Z, Cushman L, Johnson B: Estimation of product of lipid peroxidation malondialdehyde in biochemical systems. Anal Biochem, 1966, 16, 359-364.
57. Prior RL, Cao G: In vivo total antioxidant capacity: comparison of different analytical methods. Free Radical Biol Med, 1999, 27, 1173-1181.
58. Qutkin FM, Petkova E, McGrath PJ, Taylor B, Beasley C, Stewart J, Amsterdam J et al.: When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry, 2003, 160, 734-740.
59. Raison ChL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol, 2006, 27, 24-31.
60. Sarandol A, Sarandol E, Eker S, Erdinc S, Vatansever E, Kirli S: Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative system. Hum Psychopharmacol, 2007, 22, 67-73.
61. Sarandol A, Sarandol E, Eker SS, Karaagac EU, Hizli BZ, Drican M, Kirli S: Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry, 2006, 30, 1103-1108.
62. Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29, 2, 201-217.
63. Sengpiel B, Preis E, Krieglstein, Prehn JH: NMDA-induced superoxide production and neurotoxicity in cultured rat hippocampus neurons: role of mitochondria. Eur J Neurosci, 1998, 10, 1903-1910.
64. Selley ML: Increased (E)-4-hydroxy-2-nonenel and asymmetric dimethylarginine concentration and decreased nitric oxide concentration in the plasma of patients with major depression. J Affect Disord, 2004, 80, 249-256.
65. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Seth PK, Srimal R, Dikshit M: A study of nitric oxide, beta-adrenergic receptor and antioxidant status in the polymorphonuclear leukocytes from the patients of depression. J Affect Disord, 2002, 72, 45-52.
66. Skibska B, Okonkwo-Józefowicz G, Goraca A: Protective effects of early administration of alpha-lipoic acid against lipopolysaccharide-induced plasma lipid peroxidation. Pharmacol Rep, 2006, 58, 399-404.
67. Smith RS: The macrophage theory of depression. Med Hypotheses, 1991, 35, 298-306.
68. Sofic E, Rustembegovic A, Kroyer G, Cao G: Serum anti-oxidant capacity in neurological, psychiatric, renal diseases and cardiomyopathy. J Neural Transm, 2002, 109, 711-719.
69. Stokes PE, Holtz A: Fluoxetine tenth anniversary update: the progress continues. Clin Ther, 1997, 19, 1135-250.
70. 2 in the central nervous system: implications for neuro-degenerative diseases. J Lipid Res, 2004, 45, 205-214.
71. 2. Biochim Biophys Acta, 2006, 1761, 1289-1300.
72. Tsuboi H, Tatsumi A, Yamamoto K, Kobayashi F, Shimoi K, Kinae N: Possible connection among job stress, depressive symptoms, lipid modulation and antioxidants. J Affect Disord, 2006, 91, 63-70.
73. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol, 2007, 39, 44-84.
74. Winterbourn Ch: Biological reactivity and biomarkers of the neutrophil oxidation, hypochlorus acid. Toxicology, 2002, 181-182, 223-227.
75. Zafir A, Banu N: Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats. Eur J Pharmacol, 2007, 572, 23-31.
76. Zautra AJ, Parrish BP, Van Puymbroeck CM, Tennen H, Davis MC, Reich JW, Irwin M.: Depression history, stress, and pain in rheumatoid arthritis patients. J Behav Med, 2007, 30, 187-197.